{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-004414","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2022-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.272374+00:00","generated_at":"2026-06-27T09:39:48.947266+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Galecto forms R&D Committee, boosts non-executive Chair option grant to 36,000 shares","bullets":["R&D Committee established; members receive $7,500/yr retainer, Chair gets additional $7,500/yr.","Non-Executive Chair annual option grant increased from 18,000 to 36,000 shares; other directors remain at 18,000.","Initial equity award of 18,000 options vests over 36 months; annual award vests over 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-004414","json":"https://secwatch.observer/filing/0001564590-22-004414.json","markdown":"https://secwatch.observer/filing/0001564590-22-004414.md","text":"https://secwatch.observer/filing/0001564590-22-004414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/0001564590-22-004414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/glto-8k_20220203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:39:48.947266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}